Development of a Benzothiazole Scaffold-Based Androgen Receptor N‑Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer

All current clinically approved androgen deprivation therapies for prostate cancer target the C-terminal ligand-binding domain of the androgen receptor (AR). However, the main transactivation function of the receptor is localized at the AR N-terminal domain (NTD). Targeting the AR NTD directly is a...

Ausführliche Beschreibung